

TDMs No. 20310 - 01

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 07/22/2009

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AZT)

Time Report Requested: 11:53:07

Route: GAVAGE

CAS Number: 30516-87-1

First Dose M/F: NA / 11/18/04

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C Number: C20310C

Lock Date: 12/01/2008

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include 917 Vehicl PND1-8 F Include 918 AZT 40 PND1-8 F

Study Gender: Female

TDMSE Version: 2.1.0

Test Type: 26-39 WEEKS

Time Report Requested: 11:53:07

Route: GAVAGE

First Dose M/F: NA / 11/18/04

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

**C3B6F1-+/Trp53(tm1Brd) NCTR MICE
FEMALE**
Vehicle PND1-8 F**AZT 40 PND1-8 F**

Disposition Summary

Animals Initially in Study	26	26
Early Deaths		
Survivors		
Moribund Sacrifice		3
Natural Death	1	
Terminal Sacrifice	25	23
Animals Examined Microscopically	26	26

ALIMENTARY SYSTEM

Intestine Large, Cecum	(25)	(26)
Hyperplasia, Lymphoid	3 [2.0]	
Liver	(25)	(26)
Basophilic Focus		1
Infiltration Cellular, Lymphocyte	2 [1.0]	1 [1.0]
Inflammation, Chronic Active	2 [1.0]	
Tension Lipidosis	3 [1.3]	4 [1.5]
Vacuolization Cytoplasmic	12 [1.0]	6 [1.0]
Salivary Glands	(25)	(26)
Infiltration Cellular, Lymphocyte	15 [1.1]	12 [1.2]

CARDIOVASCULAR SYSTEM

Heart	(25)	(26)
-------	------	------

ENDOCRINE SYSTEM

Adrenal Cortex	(26)	(26)
Subcapsular, Hyperplasia	23 [1.2]	24 [1.1]
Thyroid Gland	(26)	(26)
Degeneration		1 [1.0]
Ectopic Thymus	2	1

GENERAL BODY SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:53:07

Route: GAVAGE

First Dose M/F: NA / 11/18/04

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle PND1-8 F	AZT 40 PND1-8 F
None		
GENITAL SYSTEM		
Ovary	(26)	(26)
Cyst	4 [2.3]	1 [2.0]
Uterus	(26)	(26)
Infiltration Cellular, Polymorphonuclear	1 [2.0]	
Endometrium, Hyperplasia, Cystic	4 [1.5]	3 [1.7]
Lumen, Dilatation	16 [1.5]	13 [1.2]
HEMATOPOIETIC SYSTEM		
Bone Marrow	(25)	(26)
Lymph Node	(0)	(2)
Renal, Hyperplasia, Lymphoid		1 [1.0]
Lymph Node, Mandibular	(25)	(25)
Hyperplasia, Lymphoid		1 [1.0]
Lymph Node, Mesenteric	(25)	(26)
Hyperplasia, Lymphoid	4 [1.5]	3 [1.0]
Spleen	(26)	(26)
Hematopoietic Cell Proliferation	2 [3.0]	2 [2.0]
Hyperplasia, Lymphoid	6 [2.3]	6 [2.2]
Thymus	(25)	(25)
Cyst, Multiple		1 [4.0]
Hyperplasia, Lymphoid	1 [2.0]	3 [1.3]
INTEGUMENTARY SYSTEM		
Mammary Gland	(26)	(26)
MUSCULOSKELETAL SYSTEM		
None		
NERVOUS SYSTEM		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:53:07

Route: GAVAGE

First Dose M/F: NA / 11/18/04

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle PND1-8 F	AZT 40 PND1-8 F
Brain, Brain Stem	(26)	(26)
Brain, Cerebellum	(26)	(26)
Brain, Cerebrum	(26)	(26)
Mineralization	2 [1.0]	4 [1.0]
RESPIRATORY SYSTEM		
Lung	(26)	(26)
Infiltration Cellular, Lymphocyte		1 [2.0]
Inflammation, Chronic Active		1 [1.0]
SPECIAL SENSES SYSTEM		
Harderian Gland	(25)	(26)
URINARY SYSTEM		
Kidney	(25)	(26)
Infiltration Cellular, Lymphocyte	9 [1.1]	5 [1.0]
Urinary Bladder	(25)	(26)
Infiltration Cellular, Lymphocyte	2 [1.0]	3 [1.0]
Lumen, Dilatation	1 [4.0]	

*** END OF REPORT ***